Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia"

Infect Dis Ther. 2023 Jan;12(1):301-302. doi: 10.1007/s40121-022-00727-4. Epub 2022 Nov 22.
No abstract available

Publication types

  • Letter